MRC-AML10: Protocol flow chart. *Autologous BMT reserved for second remission therapy if relapse occurred. DAT 3 + 10: Daunorubicin 50 mg/m² slow intravenous (IV) push days 1, 3, 5; cytarabine 100 mg/m² 12-hourly IV push days 1 through 10; 6-thioguanine 100 mg/m² 12-hourly orally days 1 through 10. ADE 10 + 3 + 5: Daunorubicin 50 mg/m² slow IV push days 1, 3, 5; cytarabine 100 mg/m² 12-hourly IV push days 1 through 10; etoposide (VP-16) 100 mg/m² IV (1-hour infusion) days 1 through 5. DAT 3 + 8: As DAT 3 + 10 but cytarabine and 6-thioguanine days 1 through 8 only. ADE 8 + 3+ 5: As ADE 10 + 3 + 5 but cytarabine days 1 through 8 only. MACE: Amsacrine (m-amsa) 100 mg/m² IV (1-hour infusion) days 1 through 5; cytarabine 200 mg/m² IV (continuous infusion) days 1 through 5; etoposide 100 mg/m² IV (1-hour infusion) days 1 through 5. MidAC: Mitozantrone 10 mg/m² IV (short infusion) days 1 through 5; cytarabine 1.0 g/m² IV (short infusion) days 1 through 5. NB: All doses were reduced by 25% for children less than 1 year old.